United States - English - NLM (National Library of Medicine)

mylan institutional inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlle

United States - English - NLM (National Library of Medicine)

sun pharmaceutical industries, inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 10 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematically evaluated in controlle

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride 50 mg - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica

Canada - English - Health Canada

duchesnay inc - thioridazine hydrochloride - tablet - 10mg - thioridazine hydrochloride 10mg - phenothiazines

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - thioridazine hydrochloride - film coated tablets - thioridazine hydrochloride 10 mg - thioridazine - ridazin is indicated only for schizophrenic patients who fail to show an acceptable response to adequate courses of treatment with other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects. thioridazine has not been systematically evaluated in controlled trials in treatment refractory schizophrenic patients and its efficacy in such patients is unknown.

United States - English - NLM (National Library of Medicine)

remedyrepack inc. - thioridazine hydrochloride (unii: 4wci67nk8m) (thioridazine - unii:n3d6tg58ni) - thioridazine hydrochloride tablets are indicated for the management of schizophrenic patients who fail to respond adequately to treatment with other antipsychotic drugs. due to the risk of significant, potentially life threatening, proarrhythmic effects with thioridazine treatment, thioridazine hydrochloride tablets should be used only in patients who have failed to respond adequately to treatment with appropriate courses of other antipsychotic drugs, either because of insufficient effectiveness or the inability to achieve an effective dose due to intolerable adverse effects from those drugs. consequently, before initiating treatment with thioridazine hydrochloride tablets, it is strongly recommended that a patient be given at least two trials, each with a different antipsychotic drug product, at an adequate dose, and for an adequate duration (see warnings and contraindications). however, the prescriber should be aware that thioridazine hydrochloride tablets have not been systematica

Canada - English - Health Canada

pharmascience inc - thioridazine hydrochloride - tablet - 10mg - thioridazine hydrochloride 10mg - phenothiazines

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - thioridazine hydrochloride 10mg;  ;   - tablet - 10 mg - active: thioridazine hydrochloride 10mg     excipient: colloidal silicon dioxide dextrates lactose monohydrate magnesium stearate microcrystalline cellulose opadry green pregelatinised maize starch purified talc purified water sodium starch glycolate

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - thioridazine hydrochloride 10mg;   - tablet - 10 mg - active: thioridazine hydrochloride 10mg   excipient: carnauba wax colloidal silicon dioxide hypromellose lactose monohydrate macrogol 400 magnesium stearate maize starch povidone purified talc titanium dioxide